

1 Predicting Future Development of Stress-Induced Anhedonia From Cortical Dynamics and Facial Expression

2
3 Austin A. Coley^{1,2}, Kanha Batra^{1,3}, Jeremy M. Delahanty^{1,6}, Laurel R. Keyes^{1,6}, Rachele Pamintuan^{1,3}, Assaf
4 Ramot³, Jim Hagemann⁸, Christopher R. Lee^{1,3,4,6}, Vivian Liu^{1,3}, Harini Adivikolanu^{1,3}, Jianna Cressy^{1,3,5},
5 Caroline Jia^{1,3,5}, Francesca Massa^{1,3}, Deryn LeDuke^{1,3}, Moumen Gabir^{1,3}, Bra'a Durubeh^{1,3}, Lexe Linderhof^{1,3},
6 Reesha Patel^{1,9}, Romy Wichmann^{1,6}, Hao Li^{1,9}, Kyle B. Fischer¹, Talmo Pereira¹, Kay M. Tye^{1,3,6,7}

7
8 ¹The Salk Institute for Biological Studies, La Jolla, CA

9 ²University of California, Los Angeles, Los Angeles, CA

10 ³University of California, San Diego, La Jolla, CA

11 ⁴Neuroscience Graduate Program, University of California, San Diego, La Jolla,

12 ⁵Medical Scientist Training Program, University of California, San Diego, La Jolla,

13 ⁶Howard Hughes Medical Institute, La Jolla, CA

14 ⁷Kavli Institute for the Brain and Mind

15 ⁸Vrije Universiteit, Amsterdam Netherlands

16 ⁹Northwestern University, Chicago, IL

17
18
19
20
21 *To Whom Correspondence Should be Addressed:

22
23 Kay M. Tye, PhD

24 Wylie Vale Professor, Salk Institute for Biological Studies

25 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.

26 tye@salk.edu

27
28 and

29
30 Austin A. Coley, PhD

31 Assistant Professor, University of California-Los Angeles

32 10833 Le Conte Ave, Los Angeles, CA 90095

33 AColey@mednet.ucla.edu

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **The current state of mental health treatment for individuals diagnosed with major depressive**
55 **disorder leaves billions of individuals with first-line therapies that are ineffective or burdened with**
56 **undesirable side effects. One major obstacle is that distinct pathologies may currently be diagnosed as**
57 **the same disease and prescribed the same treatments. The key to developing antidepressants with**
58 **ubiquitous efficacy is to first identify a strategy to differentiate between heterogeneous conditions. Major**
59 **depression is characterized by hallmark features such as anhedonia and a loss of motivation^{1,2}, and it**
60 **has been recognized that even among inbred mice raised under identical housing conditions, we**
61 **observe heterogeneity in their susceptibility and resilience to stress³. Anhedonia, a condition identified**
62 **in multiple neuropsychiatric disorders, is described as the inability to experience pleasure and is linked**
63 **to anomalous medial prefrontal cortex (mPFC) activity⁴. The mPFC is responsible for higher order**
64 **functions⁵⁻⁸, such as valence encoding; however, it remains unknown how mPFC valence-specific**
65 **neuronal population activity is affected during anhedonic conditions. To test this, we implemented the**
66 **unpredictable chronic mild stress (CMS) protocol⁹⁻¹¹ in mice and examined hedonic behaviors following**
67 **stress and ketamine treatment. We used unsupervised clustering to delineate individual variability in**
68 **hedonic behavior in response to stress. We then performed *in vivo* 2-photon calcium imaging to**
69 **longitudinally track mPFC valence-specific neuronal population dynamics during a Pavlovian**
70 **discrimination task. Chronic mild stress mice exhibited a blunted effect in the ratio of mPFC neural**
71 **population responses to rewards relative to punishments after stress that rebounds following ketamine**
72 **treatment. Also, a linear classifier revealed that we can decode susceptibility to chronic mild stress**
73 **based on mPFC valence-encoding properties prior to stress-exposure and behavioral expression of**
74 **susceptibility. Lastly, we utilized markerless pose tracking computer vision tools to predict whether a**
75 **mouse would become resilient or susceptible based on facial expressions during a Pavlovian**
76 **discrimination task. These results indicate that mPFC valence encoding properties and behavior are**
77 **predictive of anhedonic states. Altogether, these experiments point to the need for increased granularity**
78 **in the measurement of both behavior and neural activity, as these factors can predict the predisposition**
79 **to stress-induced anhedonia.**

80 Anhedonia—described as the inability to experience pleasure and hedonic feeling^{12,13}—is an underlying
81 condition and core feature observed in both schizophrenia (SCZ), major depressive disorder (MDD)¹⁴, and
82 bipolar disorder (BD)^{15,16}, and is suggested to be linked to anomalous medial prefrontal cortex (mPFC) activity⁴.
83 The mPFC, a higher order cortical region primarily responsible for cognition^{5,6}, working memory^{7,8}, sociability¹⁷,
84 and emotional control¹⁸, is also involved in valence encoding¹⁹, essential for discerning positive and negative
85 hedonic values²⁰. Stress plays a major role in disrupting mPFC processes leading to depressive-phenotypes and
86 is highly responsive to treatment. Ketamine administration shows promise as an antidepressant for treatment-
87 resistant patients and has notable effects on mPFC cortical neurons²¹⁻²³. Indeed, mPFC imaging studies in MDD
88 patients have identified biomarkers that can predict the response to therapy^{24,25}. Recently, non-invasive
89 approaches such as facial expression analysis have been utilized to capture the emotional state of a subject^{26,27}.
90 This led us to hypothesize that mPFC valence-encoding processes and behavioral features, including facial
91 expression, can predict future stress-induced phenotypes and response to ketamine.

92 **Anhedonia classification predicts associative learning performance**

93 To test this, we implemented the unpredictable chronic mild stress (CMS) protocol⁹⁻¹¹ (Fig. 1a) to induce
94 anhedonia and assessed consummatory pleasure, despair, motivation, and sociability across weeks. We used
95 sucrose preference test (SPT) as a measure of anhedonia^{9,10} and utilized unsupervised k-means clustering to
96 classify subjects into resilient and susceptible clusters (Fig. 1b-e). We then evaluated SPT scores in non-
97 stressed (control), resilient and susceptible mice. Our results showed susceptible mice display a significant
98 reduction in sucrose preference following post-stress (Fig. 1f). However, we observed no differences in sucrose
99 preference scores between non-stressed and stressed groups at the baseline, ketamine, and post-ketamine time
100 points (Fig. 1f, g).

101 Additionally, CMS mice revealed no difference in mobility during tail suspension test (TST) at baseline or
102 post-stress time points, indicating no difference in behavioral despair or motivation; but showed an increase
103 following ketamine treatment (Fig. 1h, i). These data suggest ketamine application reduces behavioral despair
104 in stressed groups compared to control mice. We observed no significant differences in mobility across groups
105 at the post-ketamine time point. Interestingly, we detected no difference in social preference in susceptible mice
106 in response to CMS (Extended Data Fig. 1).

109
110 To assess the impact of chronic stress on the neural and behavioral readouts for reward or punishment-
111 predictive cues, we trained mice that would ultimately undergo CMS or their non-stressed controls in a head-
112 fixed Pavlovian discrimination task used to discriminate reward-predictive and punishment-predictive stimuli (Fig.
113 1j). During the task, one conditioned stimulus (CS) is paired (tone) with a 30% sucrose solution delivery reward
114 (US-unconditioned stimulus), and a different conditioned stimulus is paired with a punishment air puff. We
115 observed no significant differences in anticipatory licking between stressed groups during the training phase
116 (Extended Data Fig. 2). Our results showed no difference between groups in lick probability in reward trials during
117 the anticipatory phase (following CS onset and prior to US delivery) and consummatory phase (following US
118 delivery) at the post-stress time point (Fig. 1k). Additionally, we measured lick probability during baseline,
119 ketamine, and post-ketamine time points and observed no differences between groups during the CS or US
120 phases (Extended Data Fig. 3). However, we did detect a significant correlation in lick probability and sucrose
121 preference in all mice during the conditioned stimulus at the post-stress time point; suggesting that susceptible
122 mice display both a reduction in lick probability and sucrose preference (Fig. 1l). No detectable correlation was
123 observed during the unconditioned stimulus (Fig. 1l). These findings suggest that anhedonia classification can
124 predict reward consumption performance during post-stress time points.

125 126 **Chronic stress blunts mPFC valence population dynamics and recovers at post-ketamine time point**

127 To examine the relative dynamics of responses to reward- and punishment-predictive cues, we utilized
128 longitudinal *in vivo* 2-Photon calcium imaging to track mPFC neuronal population activity (Extended Data Fig.
129 4), while mice are performing a Pavlovian discrimination task across 10 weeks during chronic mild stress and
130 ketamine treatment (Fig. 2a-c). Using a local z-score (normalized to the baseline for each trial), we applied
131 principal component analysis (PCA) to plot activity in a lower dimensional space during reward and punishment
132 trials (Extended Data Fig. 5a). We examined population dynamics across weeks in non-stressed control, resilient
133 and susceptible groups by measuring trajectory length post CS onset (0-10 sec) during reward trials and
134 punishment trials (Extended Data Fig. 5b, c). Longer trajectories reflect more dynamic population activity during
135 the trial²⁸. Our results showed no differences across groups during reward trials (Extended Data Fig. 5b). During
136 punishment trials, we observed no differences in trajectory lengths at stress time points (Extended Data Fig. 5c).

137
138 To further evaluate the evolution of responses to reward- and punishment-predictive cues in mPFC
139 neurons, we tracked and matched individual single cells over weeks and calculated the PCA trajectory length
140 reward/punishment ratio in response to chronic stress and ketamine treatment as a reflection of the relative
141 change in population dynamics (Fig. 2d; Extended Data Fig. 6a, b). Our results showed an increase in the
142 reward/punishment ratio from baseline to week 6 (post-stress time point) in control mice, indicating an increase
143 in mPFC reward processing over time (Fig. 2e). Subjects exposed to chronic mild stress displayed no difference
144 in population dynamics ratio from baseline to post-stress (Fig. 2e). We then measured the reward/punishment
145 balance from post-stress to ketamine periods, and observed no difference in control or stressed groups (Fig. 2f,
146 Extended Data Fig. 6a). Interestingly, when examining the difference from post-stress to post-ketamine time
147 points we revealed an increase in mPFC trajectory length reward/punishment ratio in stress subjects (Fig. 2g,
148 Extended Data Fig. 6b), indicating an increase in reward processing preference in both resilient and susceptible
149 groups one week following ketamine treatment. We observed no difference in reward/punishment balance in
150 control mice at post-stress to post-ketamine periods, suggesting stress-dependent changes in response to
151 ketamine (Extended Data Fig. 6b).

152 153 **mPFC population activity predicts anhedonia phenotypes prior to stress exposure**

154 To determine if mPFC population activity encodes stress-induced anhedonia behavioral phenotype
155 classification, we utilized a generalized linear model (GLM) to predict if mPFC neuronal population activity could
156 decode control, resilient and susceptible groups (Fig. 3a). We trained and tested neural data acquired from the
157 first sucrose lick during reward trials and air puff during punishment-US across weeks, and analyzed decoding
158 performance for *resilient vs control* groups, *susceptible vs control* groups, and *resilient vs susceptible* groups.
159 Our results showed there is a high decoding performance for *resilient vs control* groups compared to shuffled
160 data during first sucrose lick during individual weeks (Extended Data Fig. 7a). In *susceptible vs control* groups,
161 we observed a significantly greater decoding performance during sucrose lick at all time points; and most weeks
162 were distinguishable for *resilient vs susceptible* performance with the exception of week 1 (Extended Data Fig.

163 7b, c.). These data suggest that mPFC population activity can be used to discern susceptible and resilient
164 phenotypes in response to first sucrose lick.

165
166 We then compared decoding performance between stress groups at baseline, post-stress, ketamine, and
167 post-ketamine time points during first sucrose lick. Interestingly, at baseline, we observed a significant increase
168 in decoding performance in susceptible vs *control* groups compared to *resilient vs control* groups (Fig. 3b, c).
169 These data suggest that mPFC neural population activity in susceptible mice is more distinct compared to
170 resilient mice in response to reward stimuli prior to stress. Additionally, at the post-stress, ketamine, and post-
171 ketamine time points, we observed a significantly greater decoding performance in both *susceptible vs control*
172 and *resilient vs control* groups. These data indicate mPFC population activity can decode anhedonia phenotypes
173 during stress and ketamine treatment in response to first sucrose lick.

174
175 Next, we examined decoding performance in response to air puff between *resilient vs control* groups,
176 *susceptible vs control* groups, and *resilient vs susceptible* groups across weeks (Extended Data Fig. 7d-f). The
177 *susceptible vs control* groups displayed a significant increase in decoding performance compared to shuffle data
178 within individual weeks except at an early stress time point (week 2), and late stress time points (weeks 4-8)
179 (Extended Data Fig. 7e). Interestingly, we observed no significant differences in decoding performance across
180 weeks in *resilient vs control* groups or *resilient vs. susceptible* groups in response to air puff stimuli (Extended
181 Data Fig. 7d, f). These data suggest that *susceptible vs control* groups displayed distinct mPFC activity encoding
182 properties in response to air puff during stress.

183
184 To measure the difference in *resilient vs control*, *susceptible vs control*, and *resilient vs susceptible*
185 groups in response to air puff stimuli we measured the decoding performance at baseline, post-stress, ketamine,
186 and post-ketamine time points (Fig. 3d). At baseline, we were able to significantly decode resilient mice from
187 control mice, susceptible from control, and resilient from susceptible groups compared to shuffled data (Fig. 3e).
188 But we did not detect a difference amongst the *resilient vs control* compared to *susceptible vs control* at baseline
189 (Fig. 3e). During post-stress, the *resilient vs control*, *susceptible vs control*, and *resilient vs susceptible* groups
190 displayed no difference compared to shuffled data (Fig. 3e). These data demonstrate chronic mild stress ablates
191 phenotype decoding performance during punishment trials.

192 **Facial expression features decode stress phenotypes**

193
194 To further evaluate the affective state of subjects exposed to chronic stress, we utilized markerless pose
195 tracking system SLEAP to examine the facial features in response to reward and punishment trials (Fig. 4a). To
196 capture the spatiotemporal dynamics of the coordination of facial features, we extracted high dimensional facial
197 data from videos and then plotted this in reduced dimensional space using principal component analysis to track
198 facial expression dynamics in response to stress and ketamine treatment (Fig. 4b). Similar to neural analysis,
199 using a local-z-score, we examined facial dynamics prior to and across stress exposure in control, resilient and
200 susceptible groups by measuring facial trajectory length difference score (Post-event - baseline) during reward
201 trials (Supplementary Video 1). At baseline, our results show reduced facial trajectory lengths difference score
202 in susceptible mice compared to control and resilient groups (Fig. 4c). We observed opposing results at post-
203 stress, where susceptible mice displayed an increase in trajectory lengths difference score during reward trials
204 (Fig. 4e). Following ketamine administration, susceptible mice showed an increase in facial dynamics compared
205 to resilient mice (Fig. 4g). Similarity, at the post-ketamine time point, susceptible mice displayed a significant
206 increase trajectory lengths difference score compared to resilient mice (Fig. 4i).

207
208 We measured facial dynamics across weeks during stress and ketamine treatment in control, resilient,
209 and susceptible groups by analyzing trajectory lengths post-event during reward trials (Extended Data Fig. 8a-
210 c). Our results showed control mice exhibit a dramatic decrease following week 1 and remained consistent
211 through most weeks (Extended Data Fig. 8a). Interestingly, in resilient mice, we observed dramatic peaks in
212 facial trajectory lengths that began early stress (week 2), and continued late stress (week 5 and 6) and ketamine
213 time points (Extended Data Fig. 8b). In stark contrast, susceptible mice revealed increased trajectory lengths
214 during reward trials at late stress (Extended Data Fig. 8c). These data demonstrate distinct fluctuations in facial
215 dynamics within stressed groups compared to control mice, supporting the notion that facial expression dynamics
216 could provide a quantitative readout for diagnosis that would inform individualized treatment plans.

217

To test whether we could predict if facial responses to reward stimuli could decode control, resilient and susceptible groups, we applied a generalized linear model (Fig. 4d). We showed efficient decoding performance of stress groups for sucrose trials over weeks (Extended Data Fig. 9a-c). Similar to neural decoding performance, we observed a significant increase in facial decoding performance in stress phenotypes compared to shuffled data at baseline, post-stress, ketamine, and post-ketamine time points (Fig. 4d, f, h, j). Interestingly, our results also showed a significantly higher decoding performance in susceptible vs control groups compared to resilient vs control groups after ketamine administration during reward trials (Fig. 4h).

Next, we examined facial dynamics across weeks in control, resilient and susceptible groups by measuring trajectory length difference score during punishment trials. Our results showed an increase in facial trajectory length difference score at baseline in resilient groups compared to control and susceptible mice (Fig. 4k). At post-stress time points, we observed no difference across groups in response to punishment stimuli (Fig. 4m). However, following ketamine administration, resilient mice displayed reduced facial dynamics compared to control mice (Fig. 4o). These results indicate that resilient mice exhibit significantly different facial responses to punishment stimuli during both baseline and ketamine treatment. Interestingly, during the post-ketamine time point, we noticed a significant increase in trajectory length difference score in susceptible mice compared to control and resilient groups (Fig. 4q).

We then measured facial dynamics across weeks during stress and ketamine treatment in control, resilient, and susceptible groups during punishment trials (Extended Data Fig. 8d-f). Our results showed an increase in trajectory lengths in control mice following ketamine administration (Extended Data Fig. 8d). Resilient subjects exhibit a reduction in trajectory length from week 0 to week 1, but increase in week 2 and week 6 time points (Extended Data Fig. 8e). In susceptible mice, we observed a decrease at early stress time points (week 3 and 4) during punishment trials (Extended Data Fig. 8f).


To test facial decoding performance in response to air puff between stress groups, we used a GLM and showed efficient decoding performance across weeks (Extended Data Fig. 9d-f). Next, we compared decoding performance between resilient vs control groups, susceptible vs control groups, and resilient vs susceptible groups during punishment trials at baseline, post-stress, ketamine, and post-ketamine time points (Fig. 4l, n, p, r). At baseline, we noticed an increase in resilient vs. susceptible decoding performance compared to susceptible vs control (Fig. 4l). However, we observed no difference among stress groups following post-stress and ketamine application (Fig. 4n, p, r). These results confirm that facial dynamics within groups are readily detectable during punishment stimuli, but are more discernable within resilient mice prior to stress.

Conclusion

Together, these data revealed that mPFC valence-specific neural population activity and behavioral attributes predict anhedonia phenotypes. This study demonstrates that longitudinal tracking of neural populations and activity across epochs of unpredictable chronic mild stress can help identify biomarkers for depressive-like phenotypes. Stress subjects showed no difference in the reward/punishment ratio during late time points, whereas control mice displayed an increase in reward processing. Indeed, we demonstrate that mPFC neural dynamics and facial expression features can encode anhedonia at multiple time points. Susceptible mice displayed a significantly higher reward decoding performance compared to resilient mice at baseline, suggesting we can predict susceptibility prior to stress. Interestingly, chronic stress eliminates the neural decoding performance of punishment unconditioned stimuli in both resilient and susceptible groups.

We investigated the differential effects of ketamine application in both control and stressed groups, showing alleviation of anhedonia phenotypes within 24 hours that was sustained a week later. However, we demonstrate ketamine's distinct stress-dependent changes during despair assays, where control mice show a reduction in mobility compared to both resilient and susceptible groups. Our data also highlights a preference in mPFC reward processing in stressed groups one week after ketamine administration. These data support the decoding studies, showing that susceptible mice exhibit higher decoding performance compared to resilient mice, which we speculate reflects an increased sensitivity to ketamine application within PFC dynamics and associated facial feature expressions. These data could lead to ketamine response predictions and sustainability, poised for subjects exposed to chronic stress. Altogether, this study highlights the importance of longitudinal

273 data as a framework for identifying biomarkers of depressive-like phenotypes by analyzing granular behavioral
274 attributes in combination with mPFC neural dynamic population features.
275
276
277
278
279
280
281
282
283
284
285
286




293 **Figure 1: Stress-induced phenotype classification predicts reward task performance**

294 **a.** Schematic of unpredictable chronic mild stress (CMS) protocol. CMS mice were exposed to 2-3 stressors per
295 day for 6 weeks that consisted of cage tilting, strobe light illumination, white noise, crowded housing, light/dark
296 cycle manipulations, food deprivation, water deprivation, and damp bedding. **b.** Timeline of measurements for
297 sucrose preference test (SPT) and tail suspension test (TST) during CMS and ketamine treatment. **c.** The optimal
298 k elbow method uses the within-cluster-sum-of-square (WCSS) values to determine the appropriate number of
299 clusters derived from SPT scores of mice at the Post-stress time point. **d.** Cluster analysis of SPT scores for
300 susceptible (cluster 1), neutral (cluster 2), and resilient (cluster 3) groups. Significant decrease in SPT scores
301 from susceptible mice compared to neutral mice (One-way ANOVA, between-subjects $F_{(2,21)}=100.3$, $p<0.0001$.
302 Tukey Post-hoc, $p<0.0001$). Significant decrease in SPT scores from neutral mice compared to resilient mice
303 ($p<0.0001$). Significant increase in SPT scores from resilient mice compared to susceptible mice ($p<0.0001$). **e.**
304 To determine resilient (dark blue and light blue), and susceptible (red) subjects, k-means clustering ($k=3$) of
305 sucrose preference scores was applied in both stressed ($n=8$) and non-stressed control (gray) groups ($n=14$). **f.**
306 Susceptible mice displayed a reduction in SPT scores compared to control and resilient mice at the Post-stress
307 time point (One-way ANOVA, $F_{(2,21)}=16.95$, $p<0.0001$, Tukey Post-hoc: control compared to resilient mice,
308 $p=0.8051$, control compared to susceptible mice, $p=0.0003$, susceptible compared to resilient mice, $p<0.0001$).
309 No differences were observed at Baseline (One-way ANOVA, $F_{(2,21)}=0.4606$, $p=0.6371$), Ketamine (One-way
310 ANOVA, $F_{(2,20)}=0.4637$, $p=0.6356$) or Post-Ketamine time points (One-way ANOVA, $F_{(2,20)}=0.4364$, $p=0.6524$).
311 **g.** Longitudinal description showing non-stressed control mice (left) and stressed (resilient, neutral, and
312 susceptible) mice during sucrose preference test. **h.** Susceptible and resilient mice displayed an increase in
313 mobility compared to control mice during TST at the Ketamine time point (One-way ANOVA, $F_{(2,20)}=5.376$,
314 $p=0.0135$, Tukey Post-hoc: control compared to resilient mice, $p=0.0309$; control compared to susceptible mice,
315 $p=0.0246$; resilient compared to susceptible mice, $p=0.9187$. No differences in mobility across groups during
316 Baseline (One-way ANOVA, $F_{(2,21)}=0.3632$, $p=0.6997$), Post-stress (One-way ANOVA, $F_{(2,21)}=1.185$, $p=0.3253$),
317 and Post-Ketamine (One-way ANOVA, $F_{(2,20)}=2.702$, $p=0.0915$) time points. **i.** Longitudinal description showing
318 non-stressed control mice (left) and stressed (resilient, neutral, and susceptible) mice during tail suspension test.
319 **j.** Pavlovian discrimination paradigm in a head-fixed mouse showing US paired with a 5-second pure tone as the
320 conditioned stimulus (CS (+)), with the tone frequency set at 9 kHz for the rewarding CS (sucrose), and a 5-
321 second pure tone as the conditioned stimulus (CS (-)), with the tone frequency set at 2 kHz for the punishment
322 CS (Air Puff). **k.** Peri-stimulus time histogram (PSTH) of lick probability during reward trials in control, resilient,
323 and susceptible mice. **l.** Significant correlation in lick of lick probability and sucrose preference test during CS at
324 Post-stress time point (Pearson's correlation of lick probability and sucrose preference test in control, resilient,
325 and susceptible mice. left, Pre-US, $r=0.44$, $p=0.03$; right, Post-US, $r=0.07$, $p=0.71$). Data in bar graphs are shown
326 as mean and error bars around the mean indicate s.e.m. NS, not significant

327
328
329
330

331
332
333
334
335
336
337
338
339
340
341
342
343
344



345
346
347
348
349
350
351

352 **Figure 2: Chronic stress blunts mPFC valence population dynamics ratio while a single dose of**
353 **ketamine reverses this effect**

354 **a.** Head-fixed mouse and example mPFC 2-Photon image highlighting region of interest (ROI) neurons.
355 Experimental paradigm shows the timeline of longitudinal 2-Photon imaging sessions. **b.** Pavlovian
356 discrimination paradigm task showing Sucrose Reward trials (US paired with a 5-second tone (CS+)) and Air
357 puff Punishment trials (US paired with a 5-second tone (CS-)). **c.** Example df/f traces of mPFC neurons. **d.** To
358 explore population dynamics, we applied principal component analysis (PCA) of neural trajectories of ROI
359 matched (co-registered) mPFC neurons during reward trials (Top) and punishment trials (Bottom) showing
360 control (gray), resilient (blue), and susceptible (red) groups in a lower dimensional common principal component
361 (PC) sub-space from Baseline to Post-stress time points. The first PCs capture 42.97% of the variance. The top
362 23 PCs were used to capture 59.51% of the variance. **e.** To examine the reward and punishment population
363 dynamics we examined we used a super global Z-score (Z-score normalized across multiple sessions) and
364 measured the trajectory lengths (post-event, 0-10 sec) during reward and punishment trials in pairwise (time
365 point matched) ROI matched co-registered neurons and calculated the reward/punishment ratio during baseline
366 to post-stress time points. Control mice showed an increase in reward/punishment ratio over time; Control (left),
367 paired t-test, $p=0.0031$. Stressed mice showed no difference: CMS (right), paired t-test, $p=0.3805$. Significant
368 decrease in trajectory length ratio (ratio normalized to baseline time point) in CMS mice compared to control
369 mice. Bar graph: unpaired t-test, $p=0.0031$. **f.** No significant differences were observed in pairwise ROI matched
370 neural trajectory lengths (post-event, 0-10 sec) reward/punishment ratio during Post-stress to Ketamine time
371 points: Control (left), paired t-test, $p=0.4520$; CMS (right), paired t-test, $p=0.8203$. Bar graph: unpaired t-test,
372 $p=0.6929$ **g.** Stressed groups showed an increase in reward/punishment ratio in pairwise ROI matched neural
373 trajectory lengths (post-event, 0-10 sec) reward/punishment ratio during Post-stress to Post-Ketamine time
374 points CMS (right), paired t-test, $p=0.0475$. No significant differences were observed in control groups. Control
375 (left), paired t-test, $p=0.0774$. Significant increase in trajectory length ratio (ratio normalized to Post-stress time
376 point) in CMS mice compared to control mice. Bar graph: unpaired t-test, $p=0.0277$. * $p<0.05$, ** $p<0.01$.
377

378

379

380

381

382

383

384

385

386

387


388

389

390

391

392



393


394

395

396

Figure 3: mPFC population dynamics predicts future resilience or susceptibility, before stress exposure

a. Schematic depicts feature and label inputs for the generalized linear model classifier used for decoding performance. b. Decoding performance across time during the first sucrose lick following US presentation (reward trials) in *resilient vs control* groups (blue), *susceptible vs control* groups (red), and *resilient vs. susceptible* groups (purple) at Baseline, Post-stress, Ketamine, and Post-Ketamine time points. c. Decoding performance during Sucrose lick (first lick following sucrose presentation). *Susceptible vs control* groups displayed a significantly greater decoding performance than *resilient vs control* groups at Baseline (Two-way ANOVA, event $F_{(1,27)}=86.98$, $p<0.0001$, groups $F_{(2,27)}=11.91$, $p=0.0002$, interaction, $F_{(2,27)}=4.175$, $p=0.0263$; Tukey Post-hoc, *resilient vs control* compared to *susceptible vs control* groups, $p=0.0010$, *resilient vs control* compared *resilient vs. susceptible* groups, $p<0.0001$). Significantly greater decoding performance in *resilient vs control* compared to *resilient vs. susceptible* groups, and *susceptible vs control* groups compared to *resilient vs. susceptible* groups at the Post-stress time point (Two-way ANOVA, event $F_{(1,27)}=58.08$, $p<0.0001$, groups $F_{(2,27)}=3.0009$, $p=0.0661$, interaction, $F_{(2,27)}=4.110$, $p=0.0277$; Tukey Post-hoc, *resilient vs control* compared to *resilient vs. susceptible* groups, $p=0.0216$, *susceptible vs control* groups compared to *resilient vs. susceptible* groups, $p=0.0019$). Stress phenotypes displayed a significantly higher decoding performance compared to shuffled data at each time point, but no differences were observed across groups at Ketamine (Two-way ANOVA, event $F_{(1,27)}=203.4$, $p<0.0001$, groups $F_{(2,27)}=3.693$, $p=0.0382$, interaction, $F_{(2,27)}=1.450$, $p=0.2522$) and Post-Ketamine time points (Two-way ANOVA, event $F_{(1,27)}=55.42$, $p<0.0001$, groups $F_{(2,27)}=4.134$, $p=0.0272$, interaction, $F_{(2,27)}=3.203$, $p=0.0564$). d. Time series traces depicting decoding performance during air puff-US (punishment trials) in *resilient vs control* groups (blue), *susceptible vs control* groups (red), and *resilient vs susceptible* groups (purple) at Baseline, Post-stress, Ketamine, and Post-Ketamine time points. e. Decoding performance during Air puff-US. Significantly greater decoding performance of *resilient vs control* groups and *Susceptible vs control* groups compared to shuffled data at Baseline (Two-way ANOVA, event $F_{(1,27)}=41.80$, $p<0.0001$, groups $F_{(2,27)}=0.2737$, $p=0.7627$, interaction, $F_{(2,27)}=1.056$, $p=0.3617$), and the Ketamine time points (Two-way ANOVA, event $F_{(1,27)}=14.46$, $p=0.0007$, groups $F_{(2,27)}=1.437$, $p=0.2552$, interaction, $F_{(2,27)}=0.9261$, $p=0.4083$), but no differences across stress groups. No difference in decoding performance of *resilient vs control* groups to shuffled data and *Susceptible vs control* groups compared to shuffled data at the Post-stress time point (Two-way ANOVA, event $F_{(1,27)}=0.3822$, $p=0.5416$, groups $F_{(2,27)}=0.6345$, $p=0.5379$, interaction, $F_{(2,27)}=1.679$, $p=0.2054$). Mice with a susceptible phenotype displayed a significantly greater decoding performance compared to shuffled data at Post-Ketamine time point, but no differences were observed across stress groups (Two-way ANOVA, event $F_{(1,27)}=65.09$, $p<0.0001$, groups $F_{(2,27)}=1.840$, $p=0.1782$, interaction, $F_{(2,27)}=1.392$, $p=0.2659$). All post-hoc comparisons are Tukey t-tests, * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ All 2-way ANOVAs were for event (event vs shuffle) and groups (*resilient vs control*, *susceptible vs control*, and *resilient vs susceptible*). Data in bar graphs are shown as mean and error bars around the mean indicate s.e.m.



449

450

451

452

453

454

Figure 4: Susceptibility and Resilience can be decoded and predicted from facial expression dynamics


455 **a.** Example image of labeled mouse facial features. **b.** To determine if we could predict future responses to
456 stress or responses to ketamine based on facial features alone, we first extracted facial keypoints from
457 using SLEAP, then plotted the facial expression dynamics in a dimensionality-reduced trajectory in time
458 across principal component space of facial expression dynamics. **c.** To measure facial dynamics, we used
459 a local Z-score, and extracted PCA trajectories (top 3 PCs capture 81.91% of the variance; 8 PCs were
460 used to capture 90.54% of the variance) of facial features at baseline (left) and difference score (right) of
461 trajectory lengths post-event (10 sec CS) – pre-event (10 sec Pre-CS). Control and resilient groups
462 displayed a significantly greater PCA difference score compared to susceptible mice. One-way ANOVA,
463 between-subjects $F_{(2,21)}=20.18$, $p<0.0001$. Tukey Post-hoc, Control compared to Resilient mice, $p=0.9994$,
464 Control compared to Susceptible mice, $p<0.0001$, Resilient compared to Susceptible mice, $p<0.0001$ **d.**
465 Significantly greater facial Decoding performance in stressed groups compared to shuffled data, but no
466 difference across stressed groups during reward trials at Baseline (Two-way ANOVA, event $F_{(1,18)}=573.2$,
467 $p<0.0001$, groups $F_{(2,36)}=3.095$, $p=0.0575$, interaction, $F_{(2,36)}=3.206$, $p=0.0523$). **e.** Susceptible groups
468 displayed a significant increase in PCA difference score compared to control and resilient groups at Post-
469 stress (One-way ANOVA, $F_{(2,21)}=9.139$, $p=0.0014$. Tukey Post-hoc, Control compared to Resilient mice,
470 $p=0.9784$, Control compared to Susceptible mice, $p=0.0045$, Resilient compared to Susceptible mice,
471 $p=0.0023$). **f.** Significantly greater facial decoding accuracy in stressed groups compared to shuffled data,
472 but no difference across groups at Post-stress time point. (Two-way ANOVA, event $F_{(1,18)}=344.3$, $p<0.0001$,
473 groups $F_{(2,36)}=0.1186$, $p=0.8885$, interaction, $F_{(2,36)}=1.898$, $p=0.1645$). **g.** Resilient mice displayed a
474 significant reduction in PCA difference score compared to control and susceptible groups at Ketamine time
475 point (One-way ANOVA, $F_{(2,15)}=15.18$, $p=0.0002$. Tukey Post-hoc, Control compared to Resilient mice,
476 $p=0.0002$, Control compared to Susceptible mice, $p=0.3646$, Resilient compared to Susceptible mice,
477 $p=0.0143$). **h.** Significantly greater decoding performance in stressed groups compared to shuffled data,
478 and a significantly greater increase in *susceptible vs control* groups compared to *resilient vs control* groups
479 at Ketamine time point (Two-way ANOVA, event $F_{(1,18)}=255.9$, $p<0.0001$, groups $F_{(2,36)}=21.30$, $p<0.0001$,
480 interaction, $F_{(2,36)}=5.525$, $p=0.0081$. Tukey Post-hoc, *control vs resilient* compared to *Control vs Susceptible*
481 groups, $p<0.0001$, *Control vs Resilient* groups compared to *Resilient vs Susceptible* groups, $p=0.0068$,
482 *Control vs Susceptible* groups compared to *Resilient vs Susceptible* groups, $p=0.0023$. **i.** Resilient mice
483 displayed a significant reduction in PCA difference score compared to control and susceptible groups at
484 Post-Ketamine time point (One-way ANOVA, $F_{(2,20)}=9.206$, $p=0.0015$. Tukey Post-hoc, Control compared to
485 Resilient mice, $p=0.0054$, Control compared to Susceptible mice, $p=0.9070$, Resilient compared to
486 Susceptible mice, $p=0.0038$. **j.** We found a significantly greater decoding performance in stressed groups
487 compared to shuffled data, and a significantly higher decoding performance in *resilient vs control* groups
488 compared to *resilient vs susceptible* groups and *Susceptible vs Control* compared to *Resilient vs*
489 *Susceptible* groups at the Post-Ketamine time point (Two-way ANOVA, event $F_{(1,18)}=665.3$, $p<0.0001$,
490 groups $F_{(2,36)}=6.825$, $p=0.0031$, interaction, $F_{(2,36)}=5.316$, $p=0.0095$. Tukey Post-hoc, *resilient vs control*
491 compared to *susceptible vs control*, $p=0.6321$, *resilient vs control* groups compared to *resilient vs*
492 *susceptible* groups, $p=0.0019$, *susceptible vs control* groups compared to *resilient vs susceptible* groups,
493 $p=0.0001$). **k.** Resilient groups displayed a significant increase in PCA difference score compared to control
494 and susceptible groups at Baseline during punishment trials (One-way ANOVA, $F_{(2,21)}=10.85$, $p=0.0006$.
495 Tukey Post-hoc, Control compared to Resilient mice, $p=0.0016$, Control compared to Susceptible mice,
496 $p>0.9999$, Resilient compared to Susceptible mice, $p=0.0023$). **l.** We observed a significantly greater
497 decoding performance in stressed groups compared to shuffled data, and a significantly greater increase in
498 *resilient vs control* compared to *susceptible vs control* groups at Baseline (Two-way ANOVA, event
499 $F_{(1,18)}=91.33$, $p<0.0001$, groups $F_{(2,36)}=7.033$, $p=0.0026$, interaction, $F_{(2,36)}=4.068$, $p=0.0255$. Tukey Post-
500 hoc, *resilient vs control* groups compared to *susceptible vs control* groups, $p=0.0077$, *resilient vs control*
501 groups compared to *resilient vs susceptible* groups, $p=0.3890$, *susceptible vs control* compared to *resilient*
502 *vs susceptible* groups, $p=0.0002$). **m.** No differences in PCA difference scores at the Post-stress time point
503 (One-way ANOVA, $F_{(2,21)}=2.884$, $p=0.0782$). **n.** Significantly greater decoding performance in stressed
504 groups compared to shuffled data, but no difference across groups at the Post-stress time point (Two-way
505 ANOVA, event $F_{(1,18)}=230.7$, $p<0.0001$, groups $F_{(2,36)}=3.343$, $p=0.0466$, interaction, $F_{(2,36)}=2.133$, $p=0.1357$).
506 **o.** Resilient mice displayed a significant reduction in PCA difference score compared to control and
507 susceptible groups at Ketamine time point (One-way ANOVA, $F_{(2,15)}=4.651$, $p=0.0268$. Tukey Post-hoc,

508 Control compared to Resilient mice, $p=0.0256$, Control compared to Susceptible mice, $p=0.9246$, Resilient
509 compared to Susceptible mice, $p=0.1224$). **p.** Significantly greater decoding performance in stressed
510 groups compared to shuffled data at Ketamine, but no difference across groups at the Ketamine time point
511 (Two-way ANOVA, event $F_{(1,18)}=70.99$, $p<0.0001$, groups $F_{(2,36)}=0.02305$, $p=0.9772$, interaction,
512 $F_{(2,36)}=1.060$, $p=0.3571$). **q.** Susceptible mice displayed a significant increase in PCA difference score
513 compared to control and resilient groups (One-way ANOVA, $F_{(2,20)}=12.58$, $p=0.0003$. Tukey Post-hoc,
514 Control compared to Resilient mice, $p=0.6814$, Control compared to Susceptible mice, $p=0.0022$, Resilient
515 compared to Susceptible mice, $p=0.0003$. **r.** Significantly greater decoding performance in stressed groups
516 compared to shuffled data at Post-Ketamine, but no difference across groups (Two-way ANOVA, event
517 $F_{(1,18)}=56.50$, $p<0.0001$, groups $F_{(2,36)}=0.2553$, $p=0.7915$, interaction, $F_{(2,36)}=0.3098$, $p=0.7355$). Data in bar
518 graphs are shown as mean and error bars around the mean indicate s.e.m.

519

520

521



522

523

524

525

526

527 **Extended Data Figure 1. Ketamine treatment after chronic mild stress decreases variance in social**
528 **index in susceptible mice.**

529 **a.** Schematic of three-chamber sociability task assessing social preference. **b.** Workflow for SLEAP automated
530 pose tracking, used to precisely quantify interaction time based on the subject's distance in pixels and angle to
531 both the social and non-social cups. **c.** No difference in social interaction across groups at Baseline, Post-stress,
532 ketamine, and Post-Ketamine time points. Social index, calculated as a ratio of time spent interacting with the
533 social cup over combined social cup and non-social cup interaction times, measured at Baseline (one-way
534 ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 20)} = 0.1539$, $p=0.8583$), Post-stress (one-way ANOVA, Tukey's
535 post hoc, interaction effect: $F_{(2, 20)}=0.09649$, $p=0.5403$), Ketamine (one-way ANOVA, Tukey's post hoc,
536 interaction effect: $F_{(2, 20)}=0.2762$, $p=0.0726$), and one week after Ketamine treatment (one-way ANOVA, Tukey's
537 post hoc, interaction effect: $F_{(2, 20)} = 3.173$, $p=0.9614$) time points. Error bars represent mean +/- SEM. **d.**
538 Standard deviation plot of social index across Baseline (Control: $n=8$, $SD=0.1338$; Resilient: $n=9$, $SD=0.1196$;
539 Susceptible: $n=5$, $SD=0.1585$), Post-stress (Control: $n=8$, $SD=0.1087$; Resilient: $n=9$, $SD=0.1255$; Susceptible:
540 $n=5$, $SD=0.1234$), Ketamine (Control: $n=8$, $SD=0.1166$; Resilient: $n=9$, $SD=0.1322$; Susceptible: $n=5$,
541 $SD=0.08842$), and after Ketamine (Control: $n=8$, $SD=0.1213$; Resilient: $n=9$, $SD=0.2082$; Susceptible: $n=5$,
542 $SD=0.1036$) time points. **e.** k-means clustering ($k=5$) of social index and sucrose preference scores. The optimal
543 k elbow method using the within-cluster-sum-of-square (WCSS) was applied to determine the appropriate
544 number of clusters derived from social index and sucrose preference scores of mice Post-stress time point.

545
546

547

548

549

550

551

552

553

554

555

556

557

558

559

560


561

562

563

564

565



566

Extended Data Figure 2. Susceptible mice show no differences in anticipatory licking during head-fixed training task prior to stress.

567

568

569

570

571

572

573

574

575

576

577

578

a. During head-fixed training, total number of anticipatory licks measured at multiple time points. No significant differences across control, resilient, and susceptible groups: day 3 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 19)} = 1.644, p = 0.2196$), day 4 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 19)} = 2.353, p = 0.1221$), day 5 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 20)} = 1.295, p = 0.2958$), day 12 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 19)} = 2.520, p = 0.1070$), day 13 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 20)} = 0.2470, p = 0.7835$), and day 14 (one-way ANOVA, Tukey's post hoc, interaction effect: $F_{(2, 21)} = 1.249, p = 0.3073$) of headfixed training. Error bars represent mean \pm SEM. **b.** Longitudinal description showing non-stressed control mice (top panel: gray) and stressed (bottom panel: resilient and susceptible) mice during headfixed training.

579

580

581

582


583

584

585

586

587





588

589 **Extended Data Figure 3. No difference in lick probability within susceptible group at Baseline,**
 590 **Ketamine, and Post-Ketamine time points.**

591 **a.** Visualizing lick probability relative to cue onset of CS (0 - 2 seconds) and sucrose delivery of US (2 - 5
 592 seconds) in control, resilient and susceptible groups during Baseline (top panel). No significant differences in
 593 lick probability across groups: Lick Probability (One-way ANOVA, Baseline CS, $F_{(2, 20)} = 0.5011$, $p = 0.6133$;
 594 Baseline US, $F_{(2, 20)} = 0.4939$, $p = 0.6175$) (middle panel). No correlation in lick probability and sucrose
 595 preference at Baseline. Pearson's correlation of lick probability and sucrose preference test Baseline CS $r =$
 596 0.08 , $p = 0.71$, Baseline US $r = -0.32$, $p = 0.12$. (bottom panel). **b.** No significant differences in lick probability
 597 across groups: Lick probability relative to cue onset of CS and sucrose delivery of US in control, resilient and
 598 susceptible groups during Ketamine time point (top panel). Lick Probability (One-way ANOVA, Ketamine CS,
 599 $F_{(2, 15)} = 0.8240$, $p = 0.4576$; Ketamine US, $F_{(2, 20)} = 0.2545$, $p = 0.7778$) (middle panel). Significant correlation in
 600 lick probability and sucrose preference at Ketamine time point during CS, but not US. Pearson's correlation of
 601 lick probability and sucrose preference test Ketamine CS $r = 0.49$, $p = 0.039^*$ Ketamine US $r = -0.07$, $p = 0.77$
 602 (bottom panel). **c.** No significant differences in lick probability across groups: Lick probability relative to cue
 603 onset of CS and sucrose delivery of US in control, resilient and susceptible groups during post-Ketamine
 604 timepoint (top panel). Lick Probability (One-way ANOVA, post-Ketamine CS, $F_{(2, 20)} = 0.0239$, $p = 0.9764$. (middle
 605 panel). No correlation in lick probability and sucrose preference at post-Ketamine. Pearson's correlation of lick
 606 probability and sucrose preference test post-Ketamine CS $r = 0.34$, $p = 0.11$, post-Ketamine US $r = 0.05$, $p = 0.82$
 607 (bottom panel).

608


609



610

611 **Extended Data Figure 4. Histological validation of injection sites and implants.**

612 **a.** Representative images of GRIN lens implant and GCaMP7f expression in the PFC **b.** GRIN lens implant
613 locations and GCaMP7f injection sites in the mPFC for in vivo 2-photon calcium recording (Bregma 1.54 to 1.98
614 mm). x indicates viral injection site.



615

616 **Extended Data Figure 5. Visualizing neural population activity as neural trajectories using local Z-score**
 617 **revealed no differences across weeks.**

618

619 **a.** Neural trajectory lengths (post-event, 0-10 sec) in control, resilient, and susceptible groups during reward
 620 trials and punishment trials (using principal components that captured 90% of variance) across weeks. **b.**
 621 Reward (Left panel): Mixed ANOVA: subjects, $F_{(1,928, 109.9)}=8.184$, $p=0.0006$, weeks, $F_{(9,114)}=1.638$, $p=0.1127$,
 622 interaction, $F_{(18,114)}=4.126$. **c.** Punishment (Right panel): subjects, $F_{(1,984, 113.1)}=8.475$, $p=0.0004$, weeks,
 623 $F_{(9,114)}=1.154$, $p=0.3313$, $p<0.0001$, interaction, $F_{(18,114)}=3.140$, $p=0.0001$.

624

625

626

627


628

629

630

631

632



633

634

635

636

637

638

639


640

641

642

Extended Data Figure 6. Neural trajectories of longitudinally imaged ensembles during Post-stress to Ketamine time points, and Post-stress to Post-Ketamine time points.

a. Using neural trajectories of mPFC neural populations plotted with a super global Z-score (Z-score normalized across multiple sessions), ROI-matched populations between sessions during reward (Top) and punishment trials (Bottom) at Post-stress and Ketamine time points. **b.** ROI matched neural trajectories of mPFC neural populations during reward (Top) and punishment trials (Bottom) at Post-stress and Post-Ketamine time points.



643

644

Extended Data Figure 7. mPFC population activity decodes stress phenotypes.

645

a. Significant decoding performance of *resilient vs control* groups compared to shuffled data. Decoding accuracy

646

in response to sucrose lick in *resilient vs control* groups across weeks. Two-way Repeated Measures ANOVA,

647

event $F_{(1,18)}=143.5$, $p<0.0001$, weeks $F_{(3.899,70.17)}=2.145$, $p=0.0858$, interaction $F_{(9,162)}=1.309$, $p=0.2361$.

648

b. Significant decoding performance of *susceptible vs control* groups compared to shuffled data within individual

649

weeks. Decoding accuracy in response to sucrose lick in *susceptible vs control* groups across weeks. Two-way

650

Repeated Measures ANOVA, event $F_{(1,18)}=197.2$, $p<0.0001$, weeks $F_{(3.788,68.18)}=4.813$, $p=0.0021$, interaction

651

$F_{(9,162)}=4.230$, $p<0.0001$. Tukey Post-hoc, Weeks 0-9: $p<0.0001$, $p<0.0001$, $p<0.0001$, $p<0.0001$, $p=0.0014$,

652

$p=0.0001$, $p=0.0004$, $p<0.0001$, $p=0.0001$, $p=0.0003$.

c. Significant decoding performance of *resilient vs*

653 *susceptible groups* compared to shuffled data within individual weeks. Decoding accuracy in response to sucrose
654 lick in *resilient vs susceptible* groups across weeks. Two-way Repeated Measures ANOVA, event $F_{(1,18)}=234.8$,
655 $p<0.0001$, weeks $F_{(4.550,81.91)}=5.171$, $p=0.0005$, interaction $F_{(9,162)}=3.633$, $p=0.0004$. Tukey Post-hoc, Weeks 0-9:
656 $p=0.0001$, $p=0.1186$, $p=0.0171$, $p=0.0003$, $p<0.0001$, $p=0.0007$, $p=0.0384$, $p<0.0001$, $p=0.0081$, $p=0.0055$. **d.**
657 No significant difference in decoding performance of *resilient vs control groups* compared to shuffled data across
658 weeks. Decoding accuracy in response to Air puff in *resilient vs control* groups across weeks. Two-way Repeated
659 Measures ANOVA, event $F_{(1,18)}=72.28$, $p<0.0001$, weeks $F_{(4.292,77.26)}=1.041$, $p=0.3943$, interaction $F_{(9,162)}=0.5241$,
660 $p=0.8556$. **e.** Significant decoding performance of *susceptible vs control groups* compared to shuffled data within
661 individual weeks, but not week 2, and weeks 4-8. Decoding accuracy in response to Air puff in susceptible vs
662 *control* groups across weeks. Two-way ANOVA, event $F_{(1,18)}=51.47$, $p<0.0001$, weeks $F_{(5.353,96.35)}=3.086$,
663 $p=0.0028$, interaction $F_{(9,162)}=1.883$, $p=0.0579$. Tukey Post-hoc, Weeks 0-9: $p=0.0105$, $p=0.0017$, $p=0.5491$,
664 $p=0.0036$, $p=0.1050$, $p=0.7347$, $p=0.7196$, $p=0.1682$. **f.** No significant difference in decoding performance of
665 *resilient vs susceptible groups* across weeks. Decoding accuracy in response to Air puff in *resilient vs susceptible*
666 groups across weeks. Two-way Repeated Measures ANOVA, event $F_{(1,18)}=7.780$, $p=0.0121$, weeks
667 $F_{(4.555,81.99)}=2.203$, $p=0.0676$, interaction $F_{(9,162)}=2.225$, $p=0.0229$. All post-hoc comparisons are Tukey t-tests,
668 * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ All 2-way ANOVAs were for event (event vs shuffle) and weeks (0-
669 9).

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686


687

688

689

690


691



693 **Extended Data Figure 8. Resilient mice display increase in facial feature dynamics during chronic stress**

694 **a.** Significant reduction in PCA trajectory lengths from week 0 to week 1 in control mice. Trajectory lengths post-
695 event (0-10 sec at on-set of CS) during reward trials. Mixed ANOVA control mice (top): weeks, $F_{(1.367, 10.64)}=29.06$,
696 $p=0.0001$. Tukey Post-hoc, $p=0.0114$ **b.** Significant reduction in PCA trajectory lengths from week 0 to week 1,
697 and increases in week 2, 5, 6, and Ketamine weeks in resilient mice. resilient groups (middle): weeks, $F_{(2.777,$
698 $20.98)}=32.17$, $p<0.0001$. Tukey Post-hoc, Weeks: 0/1, $p<0.0001$, 1/5, $p=0.0063$, 1/6, $p=0.0031$ Saline/Ketamine,
699 $p=0.0305$. **c.** Significant increase in PCA trajectory lengths at week 6 in susceptible mice (bottom): weeks, $F_{(2.030,$
700 $12.63)}=13.43$, $p=0.0007$. Tukey Post-hoc, Weeks: 0/6, $p=0.0212$. **d.** Significant increase in PCA trajectory lengths
701 at Ketamine in control mice. Trajectory lengths post-event (0-10 sec at on-set of CS) during punishment trials.
702 Mixed ANOVA control mice (top): weeks, $F_{(1.544, 12.08)}=17.28$, $p=0.0005$. Tukey Post-hoc, Saline/Ketamine,
703 $p=0.0171$. **e.** Significant reduction in PCA trajectory lengths from week 0 to week 3, accompanied with an
704 increase from week 1 to week 6 in resilient mice. resilient mice (middle): weeks, $F_{(1.308, 11.04)}=20.67$, $p=0.0005$.
705 Tukey Post-hoc, Weeks, 0/3, $p=0.0237$, 1/6, $p=0.0014$. **f.** Significant reduction in PCA trajectory lengths from
706 week 0 to week 3, and week 0 to week 4 in susceptible mice. Susceptible mice (bottom): weeks, $F_{(1.483,$
707 $8.242)}=13.19$, $p=0.0039$. Tukey Post-hoc, Weeks, 0/3, $p=0.0012$, 0/4, $p=0.0192$. All post-hoc comparisons are
708 Tukey t-tests, * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

709
710
711
712
713
714
715



716

717

718

719

720

721

722

723

Extended Data Figure 9. Facial dynamics are sufficient to decode stress phenotype across weeks and trial type.

a. Significant decoding performance of *resilient vs control* groups compared to shuffled data within individual weeks. Decoding accuracy in response to sucrose in *resilient vs control* groups across weeks. Two-way Repeated Measures ANOVA, event $F_{(1,18)}=2222$, $p<0.0001$, weeks $F_{(5,600, 100,8)}=9.127$, $p<0.0001$, interaction $F_{(9,162)}=12.34$, $p<0.0001$. Tukey Post-hoc, Weeks 1-9: $p<0.0001$. **b.** Significant decoding performance of

724 *susceptible vs control groups* compared to shuffled data within individual weeks. Decoding accuracy in response
725 to sucrose in *susceptible vs control* groups across weeks. Two-way Repeated Measures ANOVA, event
726 $F_{(1,18)}=4044$, $p<0.0001$, weeks $F_{(4.661,83.90)}=5.680$, $p=0.0002$, interaction $F_{(9,162)}=4.642$, $p<0.0001$. Tukey Post-hoc,
727 Weeks 1-9: $p<0.0001$. **c.** Significant decoding performance of *resilient vs susceptible groups* compared to
728 shuffled data within individual weeks. Decoding accuracy in response to sucrose in *resilient vs susceptible*
729 groups across weeks. Two-way Repeated Measures ANOVA, event $F_{(1,18)}=5261$, $p<0.0001$, weeks
730 $F_{(5.097,91.75)}=8.356$, $p<0.0001$, interaction $F_{(9,162)}=7.673$, $p<0.0001$. Tukey Post-hoc, Weeks 1-9: $p<0.0001$. **d.**
731 Significant decoding performance of *resilient vs control groups* compared to shuffled data within individual
732 weeks. Decoding accuracy in response to Air puff in *resilient vs control* groups across weeks. Two-way Repeated
733 Measures ANOVA, event $F_{(1,18)}=468.2$, $p<0.0001$, weeks $F_{(5.367,96.61)}=1.764$, $p=0.1225$, interaction $F_{(9,162)}=2.074$,
734 $p=0.0347$. **e.** Significant decoding performance of *susceptible vs control groups* compared to shuffled data within
735 individual weeks. Decoding accuracy in response to Air puff in *susceptible vs control* groups across weeks. Two-
736 way ANOVA, event $F_{(1,18)}=238$, $p<0.0001$, weeks $F_{(5.381,96.85)}=1.603$, $p=0.1618$, interaction $F_{(9,162)}=1.108$,
737 $p=0.3602$. **f.** Significant decoding performance of *resilient vs susceptible groups* compared to shuffled data within
738 individual weeks. Decoding accuracy in response to Air puff in *resilient vs susceptible* groups across weeks.
739 Two-way Repeated Measures ANOVA, event $F_{(1,18)}=322.4$, $p<0.0001$, weeks $F_{(5.184,93.31)}=1.463$, $p=0.2075$,
740 interaction $F_{(9,162)}=1.743$, $p=0.0831$. All post-hoc comparisons are Tukey t-tests, **** $p<0.0001$ All 2-way ANOVAs
741 were for event (event vs shuffle) and weeks (0-9).

742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776

Supplementary Video 1. Facial expression features aligned with mPFC neural population firing

Video depicts SLEAP labels on mouse face (top right), facial feature trajectories (bottom right), mPFC neuronal firing (top right), and neural trajectories (bottom right) during reward trial.

777
778
779
780
781

782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826

Table 1 Features computed and used for facial expression.

Type	Feature name
Distance between 2 key-points, normalized to length of sucrose spout	inner eye to bottom whisker stem
	inner eye to mouth lower
	inner eye to mouth upper
	inner eye to nose tip
	inner eye to nose upper
	inner eye to nostril right
	inner eye to outer eye
	inner eye to top whisker stem
	lower eye to bottom whisker stem
	lower eye to inner eye
	lower eye to mouth lower
	lower eye to mouth upper
	lower eye to nose tip
	lower eye to nose upper
	lower eye to nostril right
	lower eye to outer eye
	lower eye to top whisker stem
	mouth lower to bottom whisker stem
	mouth lower to top whisker stem
	mouth upper to bottom whisker stem
	mouth upper to mouth lower
	mouth upper to top whisker stem
	nose tip to bottom whisker stem
	nose tip to mouth lower
	nose tip to mouth upper
	nose tip to nostril right
	nose tip to top whisker stem
	nose upper to bottom whisker stem
	nose upper to mouth lower
	nose upper to mouth upper
	nose upper to nose tip
	nose upper to nostril right
	nose upper to top whisker stem
	nostril right to bottom whisker stem
	nostril right to mouth lower
	nostril right to mouth upper
	nostril right to top whisker stem
	outer eye to bottom whisker stem
	outer eye to mouth lower
	outer eye to mouth upper
	outer eye to nose tip
	outer eye to nose upper
	outer eye to nostril right
	outer eye to top whisker stem
	top whisker stem to bottom whisker stem
upper eye to bottom whisker stem	
upper eye to inner eye	
upper eye to lower eye	
upper eye to mouth lower	
upper eye to mouth upper	
upper eye to nose tip	

	upper eye to nose upper
	upper eye to nostril right
	upper eye to outer eye
	upper eye to top whisker stem
Angle between 3 key-points	nose upper to mouth upper nose tip angle
	lower eye to inner eye to outer eye angle
	inner eye to top whisker stem to bottom whisker stem angle
	nose upper to nose tip to nostril right angle
	inner eye to nose upper to top whisker stem angle
	bottom whisker stem to nostril right to mouth upper angle
	bottom whisker stem to nostril right to nose tip angle
	bottom whisker stem to top whisker stem to nose tip angle
	nose upper to bottom whisker stem to nostril right angle
	nose upper to nose tip to top whisker stem angle
	top whisker stem to bottom whisker stem to nose tip angle
	top whisker stem to bottom whisker stem to nostril right angle
	top whisker stem to mouth upper to nostril right angle
	top whisker stem to nostril right to bottom whisker stem angle
	upper eye to inner eye to outer eye angle
Acceleration	whole eye acceleration (one frame back)
	whole eye acceleration as AUC over 5 frame window (one frame back)
	whole nose acceleration (one frame back)
	whole nose acceleration as AUC over 5 frame window (one frame back)
Velocity	whole eye velocity (one frame back)
	whole eye velocity (mean over previous ten frames)
	whole eye velocity (mean over previous 30 frames)
	whole eye velocity as AUC over 5 frame window (one frame back)
	whole eye velocity as AUC over 5 frame window (ten frames back)
	whole eye velocity as AUC over 5 frame window (30 frames back)
	whole nose velocity (one frame back)
	whole nose velocity (mean over previous ten frames)
	whole nose velocity (mean over previous 30 frames)
	whole nose velocity as AUC over 5 frame window (one frame back)
	whole nose velocity as AUC over 5 frame window (ten frames back)
	whole nose velocity as AUC over 5 frame window (30 frames back)
Area	whole nose area
	whole eye area

828

829

830

831

832

833

834 **Methods and Materials**

835 ***Animals and housing***

836 Adult, male HET DAT-Cre genotyped mice (at the minimum age of 8 weeks) arrived from Jackson
837 Laboratory (RRID: IMSRJAX:000,664) and bred at the Salk Institute, were utilized for this study. The mice
838 were housed in a reverse light cycle, with ad libitum access to food and water, until the commencement of
839 major survival surgery, behavioral tests or imaging sessions. The animals were accommodated in cages with
840 up to three littermates mates. All animal handling procedures adhered to the guidelines stipulated by the
841 National Institute of Health (NIH) and were approved by the UCSD Institutional Animal Care and Use
842 Committee (IACUC).

843 ***Stereotaxic surgery***

844 Under aseptic conditions, surgery was conducted on all subjects using a small animal stereotax (David
845 Kopf Instruments, Tujunga, CA, USA), with body temperature maintenance achieved using a heating pad.
846 Anesthesia was induced using a 5% mixture of isoflurane and oxygen, which was subsequently reduced to 2–
847 2.5% and maintained throughout the procedure (0.5 L/min oxygen flow rate). Once the subjects reached an
848 adequate level of anesthesia, measured using a toe pinch, a 1mg/kg Buprenorphine-SR injection was
849 administered subcutaneously, the ophthalmic ointment was applied to protect the eyes, hair was clipped from
850 the incision site, the area was scrubbed alternatively three times with betadine and 70% ethanol, and lidocaine
851 was subcutaneously (SQ) injected at the incision site. All measurements for viral injections were referenced
852 from Bregma as the origin. Following the surgery, the subjects were IP injected with 1mL Ringer's Lactate and
853 placed in clean cages containing water-softened mouse chow to facilitate recovery. The cages were positioned
854 on a heating pad to aid in the recovery process.

855 ***Viral injection and GRIN lens placement surgery***

856 To enable recordings from medial prefrontal cortex (mPFC) neurons, a viral approach was
857 implemented. Following the aforementioned general surgical procedures, an incision was made to expose the
858 skull. After skull leveling, craniotomies were performed above the mPFC regions. For expression of GCaMP,
859 300 nL of AAV1-hSyn-jGCaMP7f was injected into the mPFC at stereotaxic coordinates of 1.9 mm
860 anteroposterior, 0.40 mm mediolateral, and -2.2 mm dorsoventral from Bregma. The injections were carried out
861 using a 10 µL Nanofil syringe (WPI, Sarasota, FL, USA) driven at a rate of 0.1 µL/min with a microsyringe
862 pump and controller (Micro4; WPI, Sarasota, FL, USA). Following each viral injection, the needle was allowed
863 to stay in place for 5-10 minutes to allow viral material penetration before extraction. To prevent contamination,
864 the needle was thoroughly flushed with 70% ethanol and sterile water. Viral aliquots were sourced from
865 Addgene (Watertown, MA). Subsequent to viral injections, a 1 x 4 mm gradient refractive index (GRIN) lens
866 (Proview, Inscopix Inc, Mountain View, CA, USA) was inserted into the mPFC at stereotaxic coordinates of 1.9
867 mm anteroposterior, 0.4 mm mediolateral, and -2.18 mm dorsoventral from Bregma. The GRIN lens was then
868 secured to the skull and headplate using C&B Metabond and cement (Parkell), respectively.

869 ***Behavioral testing***

870 All behavioral testing occurred after a minimum of three weeks post-surgery recovery. Mice were
871 individually handled for 15 minutes each day for five days to gain familiarity with experimenters and reduce
872 stress during experiments.

873 ***Sucrose preference test***

874 The sucrose preference test (SPT) was used to measure anhedonia and was conducted in operant
875 chambers (Med Associates, Inc) placed within sound-attenuated cubicles. Each SPT session lasted for 60
876 minutes and involved the use of two electrical lickometers and a house light set at an intensity of 40 lux. The
877 lickometers were connected to bottles containing either tap water or a 1% sucrose solution in tap water. The
878 MedPC IV software (Med Associates, Inc) was utilized to detect and record each lick event. Sucrose
879 preference was calculated as (sucrose lick / (sucrose lick + water lick)) x 100. No additional food sources were
880 available within the operant chambers. To ensure variability, the bottle configuration was different in each of
881 the six operant chambers used. This allowed for repeated measures experiments, enabling animals to be re-
882 tested and re-establish learning during each session.

883 **3-Chamber Sociability test**

884 The 3-chamber sociability test was used to measure sociability and was performed in a clear
885 rectangular plexiglass arena. Prior to each session, the subject mouse is habituated in the empty arena for 3
886 minutes. Subsequently, the mouse is taken out of the arena, and a novel male mouse is placed inside a barred
887 cup on one side of the arena together with an empty barred cup on the opposite side. The subject mouse is
888 placed in the arena for 7 minutes during which footage is taken with a digital video camera above the arena.
889 Ethovision XT software (Noldus, Wageningen, Netherlands) was used to record the mice during sociability
890 assay.

891 **Tail suspension test**

892 The tail suspension test was used to measure behavioral despair. The tail of each mouse was placed
893 between two strips of autoclave labeling tape. The end of one strip of tape was then secured to a horizontal bar
894 40 cm from the ground, ensuring that the animal could not make other contact or climb during the assay. Video
895 recording was started 90 s from the time that the animal was inverted and taped. Mice will be inverted for 6
896 minutes. Time spent struggling was measured by OD-log and blind scoring each minute of video material after
897 the testing was completed and was reported in seconds for each minute of the assay.

898 **Unpredictable Chronic Mild Stress protocol**

899 To induce anhedonic symptoms, the chronic mild stress (CMS) protocol was implemented within a
900 mouse model¹¹. Mice in the CMS group were exposed to 2-3 stressors per day for 6 weeks that consisted of
901 cage tilting, strobe light illumination, white noise, crowded housing, light/dark cycle manipulations, food
902 deprivation, water deprivation, and damp bedding. CMS mice were exposed to ~3-4 hours per day besides the
903 12 hr light/dark cycle stressors. Stressors were imposed over all cages and randomized across all the days.
904 Control mice were not exposed to stressors.

905 **Ketamine administration**

906 After the 6-week chronic mild stress protocol, all mice were IP injected with saline (0.01-0.04 ml). The
907 following week all mice were IP injected with ketamine (1 mg/kg, 0.01-0.04 ml) to alleviate anhedonia. Mice
908 were allowed to recover at least 24 hours after injection before performing behavioral tasks or imaging
909 experiments.

910 **Anhedonia Classification**

911 Mice were classified following chronic mild stress using unsupervised k-means clustering method (k=3).
912 Number of clusters were determined by using the optimal k elbow method within-clusters sum of squares
913 (WCSS). Groups were classified into control (non-stressed), resilient (stressed), and susceptible (stressed)
914 groups.

915 **In Vivo 2-Photon calcium imaging**

916 **Pavlovian discrimination paradigm and trial structure**

917 In this Pavlovian paradigm, a highly palatable 30% sucrose solution (200 ms) served as the rewarding
918 unconditioned stimulus (US), while a mildly punishment air puff to the subject's face (~ 10 psi, 100 ms) acted
919 as the punishment US. Both the rewarding and punishment US were paired with a 5-second pure tone as the
920 conditioned stimulus (CS), with the tone frequency set at 9 kHz for the rewarding CS and 2 kHz for the
921 punishment CS. The reward trial started with the CS followed by a lick contingent reward US with a 2-second
922 delay. After the CS ended, the US was vacuumed away from the spout. The punishment trials started with the
923 CS followed by the punishment US with a 2-second delay. The reward and punishment catch trials both
924 consisted of the respective CS with no US. The trials were separated by a 25-30 second inter-trial interval (ITI).

925 Subjects were first head-fix trained in a closed box for 20 reward trials with no lick-contingency and no
926 US delay. Each box was equipped with a replica of the acquisition setup, without the microscope. This
927 consisted of a head-fix clamp fixed above the tube with the subject. A spout connected to a voltage recorder
928 was fixed in front of the subject. The air-puff spout and camera were fixed to opposite sides of the subject.
929 Training sessions were ramped up to 60 trials over 3 sessions, after which lick contingency was turned on with
930 a 2-second US delay for 2 sessions. Subsequently, Discrimination training sessions started, where 20% of

931 trials changed to punishment trials. Before acquisition trials started subjects were trained under the 2-photon
932 microscope for another 3 sessions. If subjects did not perform correctly anticipatory lick responses to > 50% of
933 reward trials, learning was deemed unsuccessful.

934 The acquisition sessions consisted of 8 punishment trials, 2 punishment catch trials (CS and no US), 36
935 reward trials without lick contingency, and 2 reward catch trials. These trials were pseudorandomized across
936 the two blocks, with the requirements that the first 3 trials were reward trials, there were no consecutive
937 sequences of 3 punishment trials, and the catch trials occurred in the last 15% of the trials. During each trial,
938 facial footage, in vivo calcium imaging, and lick behavior was recorded.

939 ***In vivo 2-photon calcium imaging***

940 We used a two-photon microscope (Bruker Ultima Investigator, Bruker Nano) with a 20 × objective
941 (0.45 NA, Olympus) and 920 nm excitation wavelength (Ti-Sapphire laser, Newport) for in vivo calcium
942 imaging. Images were acquired using Prairieview (Bruker Nano) in resonant-galvo acquisition mode. Each
943 field-of-view (FOV) (512 × 512 pixels covering 524 × 524 μm) was scanned at ~29.8 Hz.

944 ***Signal processing***

945 Images from 2-photon calcium imaging were processed using *Suite2P*. We used *Suite2P* to correct
946 motion artifacts, define regions of interest (ROIs) corresponding to individual neurons, and extract their
947 GCaMP fluorescence²⁹. We selected only cellular ROIs by manual curation. Sessions and trials that contained
948 motion artifacts and technical issues were taken out for further analysis. ROI match MATLAB software was
949 used to identify cells that were successfully tracked across imaging sessions.

950 ***Perfusion***

951 Following the conclusion of recording experiments subjects were deeply anesthetized with an injection
952 of sodium pentobarbital (200 mg/kg, intraperitoneal injection) and perfused transcardially with 20 mL of ice-cold
953 lactated Ringer's solution, followed by 20 mL ice-cold paraformaldehyde (4%; PFA) in phosphate-buffered
954 saline (PBS). Brains were extracted and placed in 4% PFA for 24 h. The tissue was then equilibrated in a cryo-
955 protectant solution (30% sucrose in PBS, w/v). Coronal slices measuring 60μm were taken from the tissue
956 using a sliding microtome (HM430; Thermo Fisher Scientific, Waltham, MA), and stored in PBS at 4 °C.

957 ***Epifluorescence imaging***

958 Tissue slices were imaged using an epifluorescence microscope (Keyence BZ-X). Images were taken
959 using a 2x objective lens. Following imaging, the images were evaluated to determine the location of viral
960 expression as seen via GCaMP7f. Recording sites were located using GRIN lens lesion locations.

961 ***Principal component analysis***

962 Principal component analysis (PCA) was used to measure population firing rate dynamics in the
963 mPFC³⁰. A local and global PCA was done on a matrix containing all Z-scored normalized data (Reward CS
964 tone, Punishment CS tone, Reward first lick, Reward US, Punishment US) for all animals such that we could
965 compare neural trajectories across groups (Control, Resilient, and Susceptible). For the local PCA, the matrix
966 had neurons in rows, and in the columns had mean Z-score response during -10 to 10 seconds post CS event
967 using 100 ms bins. The neural trajectories for each task-relevant event were created per group by multiplying
968 the coefficients obtained in the PCA by the mean Z-score response across trials per week. For each neural
969 trajectory, the length was calculated as the sum of Euclidean distances between adjacent 100 ms bins. Also,
970 neural trajectory distances were calculated as the Euclidean distance between the two trajectories bin-by-bin.
971 For statistical comparison analysis, the neural trajectory metrics were calculated using the leave-one-out
972 (LOO) method, leaving out all the neurons from a single animal per group, therefore the number of iterations is
973 the number of mice in that group. Thus, in every iteration the same PCA coefficients per cell were used for
974 neural trajectory analysis. For quantification of trajectory lengths and distance between trajectories the first 23
975 PCs were used to capture 59.51% of the variance. For all trajectory visualizations and trajectory
976 quantifications, we matched the number of neurons for each group (Control, Resilient, and Susceptible) for
977 comparison analysis across weeks.

979 **Generalized linear model classifier**

980 To test if anhedonia phenotype groups (Control, Resilient, and Susceptible) could be decoded during
981 reward and punishment trials from mPFC population activity, we used a generalized linear model (GLM)
982 classifier. To obtain anhedonia group mPFC population activity we used the coefficients obtained for each
983 neuron in the local PCA and created a neural trajectory using the mean Z-score responses for the Reward and
984 Punishment trials (Reward first lick and Punishment US). We trained the GLM using the first 8 PCs per session
985 per week (-10 to 10 seconds post CS event) as features. We did a 10-fold cross-validation (CV), where the
986 data was split into 10 subsets and in each iteration the training consisted of a different 90% subset of the data,
987 then the testing was done with the remaining 10% of the data. For the 10-fold CV, we computed the area under
988 the receiver operating characteristic curve (AUC score) for the test data. We used this model decode control
989 versus resilient, control versus susceptible, and resilient versus susceptible. We then compared decoding
990 performance (auROC scores) against shuffled data across weeks.

991 **SLEAP automated pose tracking analysis**

992 **Social analysis**

993 To automatically detect social interaction behaviors, SLEAP³¹ was used to estimate animal poses in
994 behavior recordings. We recorded behavior videos using Noldus EthoVision XT and a Basler GenI Cam at 25
995 frames/second, set at a fixed distance above the three-chamber arena. A training data set was labeled using a
996 12-point skeleton to represent the mouse (nose, head, neck, left ear, right ear, left forepaw, right forepaw, left
997 hindpaw, right hindpaw, trunk, tail base, tail tip), and was used to train a bottom-up model consisting of 2399
998 frames. To define interaction behavior with the social and nonsocial cups, we used a distance threshold of
999 within 1.3x pixels to the radius of the cup and an angle threshold of 90 degrees between the subject's nose,
000 body, and the center of each cup to quantify time spent interacting across frames.

001 **Facial analysis**

002 Video recordings of mouse facial expressions were collected on headfixed mice during discrimination
003 sessions. We used SLEAP³¹ version 1.2.9 (<https://github.com/talmolab/sleap>) to estimate the position of facial
004 keypoints using a 13-point custom facial skeleton. This consisted of 4 points for eye (upper_eye, lower_eye,
005 inner_eye, outer_eye,), 2 for whiskers (top_whisker_stem, bottom_whisker_stem), 4 for nose (chin
006 nose_upper, nose_tip, nostril_left, nostril_right), and 3 for mouth area (mouth_upper, mouth_lower, chin).
007 Our SLEAP model was trained on 11,154 manually labeled frames and consisted of a single-instance model
008 with UNet backbone.

009 Analysis and visualizations were executed using MATLAB. We applied a smoothing filter to the SLEAP
010 predictions using a Savitzky-Golay filter over a 5-frame window to minimize noise error associated with
011 tracking. Using a custom built MATLAB toolbox called Facial Expression Feature Extractor (FEFE), we
012 extracted from the SLEAP pose estimates various facial features such as distances between keypoints,
013 angles, velocities and accelerations of the nose and eye regions, and the areas of different facial regions as
014 documented in Table 1. To reduce the bias of camera placement on our distance based features, we
015 converted from pixels to cm by measuring the sucrose spout in each video and computing a pixel to cm
016 conversion factor for that video.

017 We performed principal component analysis (PCA) on the total feature set across all sessions,
018 normalizing each trial to a 5 s Baseline window immediately preceding that trial. To display PCA, we performed
019 a leave-one-out analysis and averaged across results. To compute trajectory lengths, we computed the
020 Euclidean norm of each subject's trajectory, then took the mean across subjects. For distance between
021 trajectories, we took the Euclidean norm of the pointwise differences of sucrose and airpuff trajectories for
022 each time step for each session; from this we also computed average distance by phenotype.

023 For facial decoding, we projected the data into PCA space, then applied a multinomial logistic
024 regression model. We used a 10-fold cross validation and compared the results to a control model where the
025 phenotype labels were shuffled in random order. The area under the curve (AUC) metric was smoothed by
026 applying a Gaussian moving average in a window using the previous 20 sec.

028 **Statistical methods**

029 The thresholds for significance were placed at * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$ unless
030 stated otherwise. All data are shown as mean and SEM. Wilcoxon signed rank-sum test, Pearson correlation,
031 one-way ANOVA, Repeated-measure ANOVA, and mixed-effects model followed by a Tukey's posthoc test
032 were performed using GraphPad Prism 6 or MATLAB. The p values were corrected for multiple comparisons.
033 Ward's linkage hierarchical clustering utilizing Euclidean distance was performed using MATLAB.

034
035
036
037
038
039
040
041
042
043
044
045
046
047
048
049
050
051
052
053
054
055
056
057
058
059
060
061
062
063
064
065
066
067
068
069
070
071
072
073
074
075
076
077
078
079
080
081

082

References:

- 083 1. *Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed.* xliv, 947 (American Psychiatric
084 Publishing, Inc., 2013). doi:10.1176/appi.books.9780890425596
- 085 2. Kennedy, S. H. Core symptoms of major depressive disorder: relevance to diagnosis and treatment.
086 *Dialogues Clin. Neurosci.* **10**, 271–277 (2008).
- 087 3. Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., Laplant, Q., Graham, A.,
088 Lutter, M., Lagace, D. C., Ghose, S., Reister, R., Tannous, P., Green, T. A., Neve, R. L., Chakravarty, S.,
089 Kumar, A., Eisch, A. J., Self, D. W., Lee, F. S., Tamminga, C. A., Cooper, D. C., Gershenfeld, H. K. &
090 Nestler, E. J. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward
091 regions. *Cell* **131**, 391–404 (2007).
- 092 4. Ferenczi, E. A., Zalocusky, K. A., Liston, C., Grosenick, L., Warden, M. R., Amatya, D., Katovich, K.,
093 Mehta, H., Patenaude, B., Ramakrishnan, C., Kalanithi, P., Etkin, A., Knutson, B., Glover, G. H. &
094 Deisseroth, K. Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior.
095 *Science* **351**, aac9698 (2016).
- 096 5. Bechara, A., Damasio, H. & Damasio, A. R. Emotion, decision making and the orbitofrontal cortex. *Cereb.*
097 *Cortex N. Y. N* 1991 **10**, 295–307 (2000).
- 098 6. Miller, E. K. & Buschman, T. J. Cortical circuits for the control of attention. *Curr. Opin. Neurobiol.* **23**, 216–
099 222 (2013).
- 100 7. Euston, D. R., Gruber, A. J. & McNaughton, B. L. The role of medial prefrontal cortex in memory and
101 decision making. *Neuron* **76**, 1057–1070 (2012).
- 102 8. Sawaguchi, T. & Goldman-Rakic, P. S. D1 dopamine receptors in prefrontal cortex: involvement in working
103 memory. *Science* **251**, 947–950 (1991).
- 104 9. Katz, R. J. Animal model of depression: Pharmacological sensitivity of a hedonic deficit. *Pharmacol.*
105 *Biochem. Behav.* **16**, 965–968 (1982).
- 106 10. Willner, P., Muscat, R. & Papp, M. Chronic mild stress-induced anhedonia: a realistic animal model of
107 depression. *Neurosci. Biobehav. Rev.* **16**, 525–534 (1992).
- 108 11. Tye, K. M., Mirzabekov, J. J., Warden, M. R., Ferenczi, E. A., Tsai, H.-C., Finkelstein, J., Kim, S.-Y.,
109 Adhikari, A., Thompson, K. R., Andalman, A. S., Gunaydin, L. A., Witten, I. B. & Deisseroth, K. Dopamine
110 neurons modulate neural encoding and expression of depression-related behaviour. *Nature* **493**, 537–541
111 (2013).
- 112 12. Pizzagalli, D. A. Depression, Stress, and Anhedonia: Toward a Synthesis and Integrated Model. *Annu.*
113 *Rev. Clin. Psychol.* **10**, 393–423 (2014).
- 114 13. Destoop, M., Morrens, M., Coppens, V. & Dom, G. Addiction, Anhedonia, and Comorbid Mood Disorder. A
115 Narrative Review. *Front. Psychiatry* **10**, 311 (2019).
- 116 14. Whitton, A. E. & Pizzagalli, D. A. Anhedonia in Depression and Bipolar Disorder. *Curr. Top. Behav.*
117 *Neurosci.* **58**, 111–127 (2022).
- 118 15. Lee, J. S., Jung, S., Park, I. H. & Kim, J.-J. Neural Basis of Anhedonia and Amotivation in Patients with
119 Schizophrenia: The role of Reward System. *Curr. Neuropharmacol.* **13**, 750–759 (2015).
- 120 16. Dimick, M. K., Hird, M. A., Fiksenbaum, L. M., Mitchell, R. H. B. & Goldstein, B. I. Severe anhedonia
121 among adolescents with bipolar disorder is common and associated with increased psychiatric symptom
122 burden. *J. Psychiatr. Res.* **134**, 200–207 (2021).
- 123 17. Forbes, C. E. & Grafman, J. The role of the human prefrontal cortex in social cognition and moral
124 judgment. *Annu. Rev. Neurosci.* **33**, 299–324 (2010).
- 125 18. Etkin, A., Egner, T. & Kalisch, R. Emotional processing in anterior cingulate and medial prefrontal cortex.
126 *Trends Cogn. Sci.* **15**, 85–93 (2011).
- 127 19. Coley, A. A., Padilla-Coreano, N., Patel, R. & Tye, K. M. Valence processing in the PFC: Reconciling
128 circuit-level and systems-level views. *Int. Rev. Neurobiol.* **158**, 171–212 (2021).
- 129 20. Tye, K. M. Neural Circuit Motifs in Valence Processing. *Neuron* **100**, 436–452 (2018).
- 130 21. Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J.,
131 Shaver, D. C., Rosenthal, D. L., Alway, E. J., Lopez, K., Meng, Y., Nellissen, L., Grosenick, L., Milner, T.
132 A., Deisseroth, K., Bito, H., Kasai, H. & Liston, C. Sustained rescue of prefrontal circuit dysfunction by
133 antidepressant-induced spine formation. *Science* **364**, eaat8078 (2019).
- 134 22. Ghosal, S., Duman, C. H., Liu, R.-J., Wu, M., Terwilliger, R., Girgenti, M. J., Wohleb, E., Fogaca, M. V.,
135 Teichman, E. M., Hare, B. & Duman, R. S. Ketamine rapidly reverses stress-induced impairments in
136 GABAergic transmission in the prefrontal cortex in male rodents. *Neurobiol. Dis.* **134**, 104669 (2020).

- 137 23. Ali, F., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S. & Kwan, A. C. Ketamine
138 disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. *Nat. Commun.* **11**, 72
139 (2020).
- 140 24. Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R. N., Zebley, B.,
141 Oathes, D. J., Etkin, A., Schatzberg, A. F., Sudheimer, K., Keller, J., Mayberg, H. S., Gunning, F. M.,
142 Alexopoulos, G. S., Fox, M. D., Pascual-Leone, A., Voss, H. U., Casey, B., Dubin, M. J. & Liston, C.
143 Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nat. Med.* **23**, 28–
144 38 (2017).
- 145 25. Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M. &
146 Kennedy, S. H. Deep Brain Stimulation for Treatment-Resistant Depression. *Neuron* **45**, 651–660 (2005).
- 147 26. Dolensek, N., Gehrlach, D. A., Klein, A. S. & Gogolla, N. Facial expressions of emotion states and their
148 neuronal correlates in mice. *Science* **368**, 89–94 (2020).
- 149 27. Moëne, O. L. & Larsson, M. A New Tool for Quantifying Mouse Facial Expressions. *eNeuro* **10**, (2023).
- 150 28. Cunningham, J. P. & Yu, B. M. Dimensionality reduction for large-scale neural recordings. *Nat. Neurosci.*
151 **17**, 1500–1509 (2014).
- 152 29. Pachitariu, M., Stringer, C., Dipoppa, M., Schröder, S., Rossi, L. F., Dalgleish, H., Carandini, M. & Harris,
153 K. D. Suite2p: beyond 10,000 neurons with standard two-photon microscopy. 061507 Preprint at
154 <https://doi.org/10.1101/061507> (2017)
- 155 30. Padilla-Coreano, N., Batra, K., Patarino, M., Chen, Z., Rock, R. R., Zhang, R., Hausmann, S. B.,
156 Weddington, J. C., Patel, R., Zhang, Y. E., Fang, H.-S., Mishra, S., LeDuke, D. O., Revanna, J., Li, H.,
157 Borio, M., Pamintuan, R., Bal, A., Keyes, L. R., Libster, A., Wichmann, R., Mills, F., Taschbach, F. H.,
158 Matthews, G. A., Curley, J. P., Fiete, I. R., Lu, C. & Tye, K. M. Cortical ensembles orchestrate social
159 competition through hypothalamic outputs. *Nature* **603**, 667–671 (2022).
- 160 31. Pereira, T. D., Tabris, N., Matsliah, A., Turner, D. M., Li, J., Ravindranath, S., Papadoyannis, E. S.,
161 Normand, E., Deutsch, D. S., Wang, Z. Y., McKenzie-Smith, G. C., Mitelut, C. C., Castro, M. D., D’Uva, J.,
162 Kislin, M., Sanes, D. H., Kocher, S. D., Wang, S. S.-H., Falkner, A. L., Shaevitz, J. W. & Murthy, M.
163 SLEAP: A deep learning system for multi-animal pose tracking. *Nat. Methods* **19**, 486–495 (2022).
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190

191 **Acknowledgments:** We thank Takaki Komiyama for technical support. Sotoris Masmanidis and Bitna Joo for
192 helpful comments on the manuscript. Salk machine shop and Salk behavior core for mechanical assistance.

193 **Funding:** A.A.C was supported by NIH/NIMH 8K00MH124182, NIH-LRP, and the Simons Collaboration on the
194 Global Brain. K.M.T. is an HHMI Investigator and the Wylie Vale chair at the Salk Institute for Biological Studies
195 and this work was supported by funding from Salk, HHMI, Clayton Foundation, Kavli Foundation, Dolby Family
196 Fund, R01-MH115920 (NIMH), R37-MH102441 (NIMH), and Pioneer Award DP1-AT009925 (NCCIH).

197
198 **Author Contributions:**

199 A.A.C and K.M.T. conceived the project, designed and supervised the experiments. A.A.C, J.D. and R.W.
200 performed stereotaxic surgeries. A.A.C, J.D., R.P., V.L., H.A., J.C., C.J., F.M., M.G., and L.L. performed
201 behavioral experiments. A.A.C, J.D., C.J., K.F. performed 2-Photon calcium-imaging experiments. A.A.C, K.B.,
202 J.D., A.R., R.P., J.H., F.M. and H.L. processed and analyzed calcium data. K.B., R.P, L.K, C.R.L, M.G, B.D., and
203 A.E. performed SLEAP automated pose tracking analysis for facial and social experiments. L.K and K.B. SLEAP
204 facial expression analysis. R.P. performed histological verifications. A.A.C, K.B., J.D., A.R., L.K., J.H., C.L., D.L.,
205 R.P., A.E., H.L., K.B. provided code scripts, edited code and offered advice for data analysis. T.P. made
206 additional significant intellectual contributions. A.A.C, K.B., and L.K graphed data and made figures. A.A.C and
207 K.M.T. wrote the paper.

208
209 **Competing Interests:** The authors declare no competing interests.

210
211 **Data and Materials Availability:** All experimental data are available in the main text or
212 supplementary material. Data will be available on an open-source database upon publication.